Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts Sells 27,199 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Allogene Therapeutics Stock Down 2.1 %

Shares of ALLO stock opened at $1.88 on Friday. The business’s 50 day moving average is $2.12 and its two-hundred day moving average is $2.51. The company has a market cap of $394.18 million, a PE ratio of -1.21 and a beta of 0.86. Allogene Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $5.78.

Institutional Investors Weigh In On Allogene Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in shares of Allogene Therapeutics in the second quarter valued at approximately $6,349,000. Lynx1 Capital Management LP acquired a new stake in Allogene Therapeutics in the 2nd quarter worth $5,192,000. Renaissance Technologies LLC grew its position in Allogene Therapeutics by 340.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after purchasing an additional 1,351,055 shares during the last quarter. Zacks Investment Management bought a new position in shares of Allogene Therapeutics during the 3rd quarter worth about $1,446,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Allogene Therapeutics by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after buying an additional 507,021 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Finally, William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).